Cost-effectiveness analyses and utility weights
Published cost-effectiveness analyses and health-state utility weights that a model of this product could cite, adapt, or compare against, grouped by how each article relates to the product and its indication. Every value is quoted from the article it cites, and section 3 lists the searches that found the articles.
9 cost-effectiveness analyses and 6 studies reporting utility weights · 11 sources
Overview
| Item | Detail |
|---|---|
| Literature searched | Tufts Medical Center Cost-Effectiveness Analysis Registry, searched October 21, 2026; the queries are listed in section 3. |
| Cost-effectiveness analyses | 9 |
| Studies reporting utility weights | 6 |
Cost-effectiveness analyses
Analyses of Tirabrutinib
No evidence found.
Treatments for the same indication
No evidence found.
The same disease in other populations or settings
High-dose methotrexate with whole-brain radiotherapy versus chemotherapy alone as induction in newly diagnosed primary central nervous system lymphoma, Canada: Prica et al. (2014)
Relevance: Evaluates high-dose methotrexate with whole-brain radiotherapy against chemotherapy alone as induction for newly diagnosed primary central nervous system lymphoma from a Canadian societal perspective, the first-line setting in which PROSPECT Part B adds tirabrutinib to methotrexate-containing regimens.
“We developed a Markov decision-analytic model to compare CMT versus chemotherapy alone for a hypothetical cohort of patients aged 60 years and newly diagnosed with PCNSL over a 5-year time horizon.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The probabilities of transitioning from one state to another were evaluated on a 3-month cycle.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Costs were derived from a societal perspective, combining the public health payer's perspective, caregiver burden, and lost productivity” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“All costs were adjusted to 2011Canadian dollars (Can$1 = US$0.96) using the Consumer Price Index” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Costs were discounted at 5%, with sensitivity analyses performed at 0% and 3%.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“In the overall group, the cost of CMT was Can$140 735, and the cost of chemotherapy alone was Can$129 430, yielding an incremental cost-effectiveness ratio of Can$506 078 per QALY.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Thus, CMT was Can$11 951 less expensive and had an expected benefit of 0.55 QALYs; the CMT strategy dominates” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Thus, chemotherapy was Can$11 244 less expensive; with no difference in QALYs; the chemotherapy alone strategy dominates” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“For the commonly accepted willingness-to-pay threshold of Can$50 000 in younger patients, CMT is the more cost-effective strategy 97% of the time, and in older patients, chemotherapy alone is the more cost-effective strategy 82% of the time” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Methotrexate, cytarabine, thiotepa, and rituximab versus methotrexate-cytarabine with or without rituximab as induction in primary central nervous system lymphoma, Canada: Beca et al. (2020)
Relevance: Compares methotrexate, cytarabine, thiotepa, and rituximab with methotrexate-cytarabine with or without rituximab as induction for primary central nervous system lymphoma, based on the IELSG32 trial, from the Canadian health care system perspective.
“This study assessed cost-effectiveness among these three induction strategies for PCNSL.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“A Markov model was developed based on the IELSG32 trial over a 20 year time horizon from the Canadian health care system perspective.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Methotrexate-cytarabine-rituximab was subject to extended dominance by the other two strategies.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“The MATRix regimen compared to methotrexate-cytarabine produced 3.05 quality-adjusted life year (QALY) gains at added costs of $75,513, resulting in an incremental cost-effectiveness ratio of $24,758/QALY gained.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“The MATRix regimen was the optimal strategy in the majority of simulations (98% probability at willingness-to-pay of $50,000/QALY gained)” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Related diseases and analogous treatments
Zanubrutinib versus ibrutinib in relapsed or refractory chronic lymphocytic leukemia, United States: Kang et al. (2024)
Relevance: Evaluates zanubrutinib against ibrutinib in relapsed or refractory chronic lymphocytic leukemia from a United States commercial payer perspective, based on the ALPINE trial.
“We aimed to evaluate the cost effectiveness of zanubrutinib versus ibrutinib in relapsed or refractory chronic lymphocytic leukemia from the commercial payer perspective in the USA.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“A partitioned survival model was developed based on survival curves from the phase III ALPINE trial.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“A discount rate of 3.0% per annum was applied and costs were adjusted to 2023 US dollars.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Over a 10-year analysis period, the incremental cost-effectiveness ratio of zanubrutinib versus ibrutinib was $91,260 per life-year gained and $120,634 per quality-adjusted life-year gained, making it cost effective within a threshold of $150,000 per quality-adjusted life-year gained.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“the probability of zanubrutinib being cost effective was approximately 52.8%, with a 30.0% likelihood of dominance.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Zanubrutinib versus ibrutinib in relapsed or refractory chronic lymphocytic leukemia, China and United States: Li et al. (2024)
Relevance: Evaluates zanubrutinib against ibrutinib in relapsed or refractory chronic lymphocytic leukemia from payer perspectives in China and the United States, based on the ALPINE study.
“This article examined the cost-effectiveness of zanubrutinib and ibrutinib for managing relapsed and refractory chronic lymphocytic leukemia from the viewpoint of payers in China and the US.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Markov models were employed to conduct comparisons. Baseline characteristics and clinical data were extracted from the ALPINE study.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“The Markov model analysis revealed that the zanubrutinib group incurred an incremental cost per patient of $-24,586.53 compared to the ibrutinib group.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“The zanubrutinib group exhibited an incremental utility per capita of 0.28 quality-adjusted life years, resulting in an incremental cost-effectiveness ratio of $-88,068.16 per quality-adjusted life year, which is lower than the payment threshold in China.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“In the US, patients in the zanubrutinib group experienced per capita incremental costs of $-79,421.56, per capita incremental utility of 0.28 quality-adjusted life years, and an incremental cost-effectiveness ratio of $-284,485.45 per quality-adjusted life year.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Ibrutinib versus rituximab plus chemotherapy in relapsed or refractory mantle cell lymphoma, United Kingdom: Tappenden et al. (2019)
Relevance: Reviews the NICE appraisal of ibrutinib against rituximab plus chemotherapy in relapsed or refractory mantle cell lymphoma from the perspective of the National Health Service and Personal Social Services.
“The company's Markov model assessed the cost effectiveness of ibrutinib versus R-chemo for the treatment of R/R MCL from the perspective of the National Health Service (NHS) and Personal Social Services over a lifetime horizon.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Based on a re-run of the company's model by the ERG, the incremental cost-effectiveness ratio (ICER) for ibrutinib versus R-chemo [including the company's original patient access scheme (PAS)] was expected to be £76,014 per quality-adjusted life-year (QALY) gained.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“The ERG's preferred analysis, which used the ERG's NMA and the observed Kaplan-Meier curve for time to ibrutinib discontinuation and excluded long-term disutilities for R-chemo, produced ICERs of £63,340 per QALY gained for the overall R/R MCL population and of £44,711 per QALY gained for patients with one prior treatment.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Following an updated PAS and consideration of evidence from a later data-cut of the RAY trial, the appraisal committee concluded that the most plausible ICER for the one prior treatment subgroup was likely to be lower than the company's estimate of £49,848 per QALY gained.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“The company's ICER for the overall R/R MCL population was higher, at £62,650 per QALY gained.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Tafasitamab with lenalidomide versus polatuzumab vedotin with bendamustine and rituximab in transplant-ineligible relapsed or refractory diffuse large B-cell lymphoma, United States: Calamia et al. (2021)
Relevance: Evaluates tafasitamab with lenalidomide, an immunomodulatory agent that section 2 lists among agents evaluated for relapsed or refractory PCNSL, against polatuzumab vedotin with bendamustine and rituximab in transplant-ineligible relapsed or refractory diffuse large B-cell lymphoma in the United States.
“We performed an industry-independent pharmacoeconomic evaluation of both regimens over a 5-year (y) time horizon (US payer perspective; 2020 USD).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Survival curves, treatment costs, and utility values were applied in a three-state Markov model (progression-free survival (PFS), post-progression survival (PPS), death) to estimate the incremental follow-up (ICER) and cost-utility ratios (ICUR).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Five-year Tafa-L costs ($470,119) exceeded PBR's ($249,217) by $220,902 with incremental gains of 0.71 life-years (LY) and 0.32 quality-adjusted life-years (QALY); yielding ICER of $310,041/LYg and ICUR of $694,241/QALYg.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Tafa-L had favorable PFS and OS rates over PBR with adjusted differences of +19.2 and +34.1%, respectively at trial follow-up (∼2 years), with corresponding 5 years differences in survival of +7.8% in PFS and +21.4% in OS.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“The incremental cost per 1% gain in the probability of achieving OR, PFS and OS at follow-up were $8,479, $6,359, and $3,583; and $28,321 and $10,323 for PFS and OS at 5 years.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Axicabtagene ciloleucel and tisagenlecleucel versus chemoimmunotherapy and stem-cell transplantation in multiply relapsed or refractory adult diffuse large B-cell lymphoma, United States: Lin et al. (2019)
Relevance: Evaluates axicabtagene ciloleucel and tisagenlecleucel, CAR T-cell therapies, which section 2 describes as investigational salvage treatment for PCNSL, against chemoimmunotherapy and stem cell transplantation in multiply relapsed or refractory large B-cell lymphoma in the United States.
“We used a decision analytic Markov model informed by recent multicenter, single-arm trials to evaluate axi-cel and tisagenlecleucel in multiply relapsed/refractory, adult, diffuse large B-cell lymphoma from a US health payer perspective over a lifetime horizon.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Under a range of plausible long-term effectiveness assumptions, each therapy was compared with salvage chemoimmunotherapy regimens and stem-cell transplantation.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Main outcomes were undiscounted life years, discounted lifetime costs, discounted quality-adjusted life years (QALYs), and incremental cost-effectiveness ratio (3% annual discount rate).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“In an optimistic scenario, assuming a 40% 5-year progression-free survival (PFS), axi-cel increased life expectancy by 8.2 years at $129,000/QALY gained (95% uncertainty interval, $90,000 to $219,000).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“At a 30% 5-year PFS, improvements in life expectancy were more modest (6.4 years) and expensive ($159,000/QALY gained [95% uncertainty interval, $105,000 to $284,000]).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“In an optimistic scenario, assuming a 35% 5-year PFS, tisagenlecleucel increased life expectancy by 4.6 years at $168,000/QALY gained (95% uncertainty interval, $105,000 to $414,000/QALY).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“At a 25% 5-year PFS, improvements in life expectancy were smaller (3.4 years) and more expensive ($223,000/QALY gained [95% uncertainty interval, $123,000 to $1,170,000/QALY]).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“At 2018 prices, it is possible that both CAR-T therapies meet a less than $150,000/QALY threshold.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Tisagenlecleucel versus salvage chemotherapy in relapsed or refractory diffuse large B-cell lymphoma, United States: Qi et al. (2021)
Relevance: Evaluates tisagenlecleucel against salvage chemotherapy in relapsed or refractory diffuse large B-cell lymphoma from a United States third-party payer perspective, a CAR T-cell therapy of the kind section 2 describes as investigational salvage treatment for primary central nervous system lymphoma.
“To assess the cost-effectiveness and cost-effective price of tisagenlecleucel, a novel, effective chimeric antigen receptor T-cell therapy, versus salvage chemotherapy (SC) for the treatment of relapsed or refractory diffuse large B-cell lymphoma (r/r DLBCL) using a willingness-to-pay (WTP) threshold of $150,000 per quality-adjusted life year (QALY) gained from a US third-party payer's perspective.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“A three-state (progression-free survival, progressive disease, and death), responder-based partitioned survival model with a lifetime horizon and 3% annual discount rate was developed.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“All costs were reported in or inflated to 2020 US dollars.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Tisagenlecleucel was associated with 3.35 QALYs gained versus SC.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“The estimated incremental costs per QALY gained versus SC were $78,652 using the wholesale acquisition cost of $373,000 for tisagenlecleucel.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“The estimated cost-effective price of tisagenlecleucel in all treated patients was $612,270 at the WTP threshold of $150,000.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Gene expression profiling-guided first-line ibrutinib with R-CHOP versus standard care in activated B-cell diffuse large B-cell lymphoma under age 60, Canada: Regier et al. (2022)
Relevance: Evaluates gene expression profiling to direct first-line ibrutinib with R-CHOP in activated B-cell diffuse large B-cell lymphoma from the perspective of the British Columbia Ministry of Health.
“The model was calibrated to evaluate the adoption of ibrutinib as a first line treatment among patients under 60 years with ABC subtype DLBCL.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The Markov model health states are: complete response (CR), treatment failure or relapse (TF/R), cure or full remission, and death.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“We discounted costs and outcomes at a rate of 1.5% per year, consistent with Canadian guidelines” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The time horizon of the model was 10 years, representing the length of time when all members of the cohort had completed treatment and were either cured or had died. Each cycle represented six months of time. The perspective of the study was from the British Columbia Ministry of Health.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“All costs were converted to 2018 Canadian dollars ($CDN) using the BC-specific consumer price index for health and personal care” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“For first-line GEP-informed treatment, the mean incremental cost was $13,226 (95% CI: 5873–20,578), and mean incremental QALYs was 0.17 (95% CI: −0.09–0.43). The resulting ICER was $77,806.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The probability that first-line GEP-informed treatment was cost-effective at a WTP of $50,000/QALY and $100,000/QALY was 24.3% and 53.7% respectively.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Utility weights
Utility weights from analyses of Tirabrutinib
No evidence found.
Utility weights for the same indication
No evidence found.
Utility weights for the same disease in other populations or settings
Utility weights for therapy, complete response with and without neurotoxicity, and incurable disease, primary central nervous system lymphoma: Prica et al. (2014)
Relevance: Utilities for primary central nervous system lymphoma on therapy, in complete response without neurotoxicity or with mild or severe neurotoxicity, and incurable disease.
“The utilities assigned to each health state were derived from a survey of expert physicians who treat patients with PCNSL.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Utility weights for related diseases and analogous treatments
Utility weights for progression-free and progressed disease and adverse events, relapsed or refractory chronic lymphocytic leukemia: Kang et al. (2024)
Relevance: Utilities for progression-free and progressed relapsed or refractory chronic lymphocytic leukemia and for adverse events, from a United States model of zanubrutinib and ibrutinib.
Access: Not open access
Not quoted: The utility weights are reported in the full text, which is closed access.
Utility weights for progression-free and post-progression survival and adverse events of polatuzumab vedotin with bendamustine and rituximab and of tafasitamab with lenalidomide, relapsed or refractory diffuse large B-cell lymphoma: Calamia et al. (2021)
Relevance: Utilities for progression-free and post-progression relapsed or refractory diffuse large B-cell lymphoma ineligible for transplant, with adverse event disutilities, from a United States model of tafasitamab with lenalidomide and of polatuzumab vedotin with bendamustine and rituximab.
Access: Free full text
Not quoted: The utility weights are reported in Table 2 and Supplementary Tables S1–S4, which the publisher's article page loads only on request and the quote checker does not read.
Utility weights for treatment and remission phases of CAR T-cell therapy, chemoimmunotherapy, and stem-cell transplantation and for progression, relapsed or refractory large B-cell lymphoma: Lin et al. (2019)
Relevance: Utilities for treatment and remission phases of CAR T-cell therapy, chemoimmunotherapy, and stem-cell transplantation and for progression in relapsed or refractory large B-cell lymphoma.
Access: Free full text
Not quoted: The utility weights are reported in the full text, which this page does not quote.
Utility weights for neurocognitive dysfunction with and without intracranial disease after prophylactic cranial irradiation, limited-stage small cell lung cancer: Qu et al. (2017)
Relevance: Utilities for neurocognitive dysfunction with and without intracranial disease after prophylactic cranial irradiation in limited-stage small cell lung cancer; section 2 lists whole-brain radiotherapy as salvage treatment for primary central nervous system lymphoma.
Access: Not open access
Not quoted: The utility weights are reported in the full text, which is closed access.
Utility weights for controlled and recurrent brain metastases and for side effects and neurocognitive decline after whole-brain radiotherapy, brain metastases: Savitz et al. (2015)
Relevance: Utilities and disutilities for side effects and neurocognitive decline after whole-brain radiotherapy and for controlled and recurrent intracranial disease.
Access: Free full text
Search strategy
| Dataset | Query | Results |
|---|---|---|
| Ratios | tirabrutinib OR "ONO-4059" | 0 |
| Ratios | "central nervous system lymphoma" OR "CNS lymphoma" | 3 |
| Weights | "central nervous system lymphoma" OR "CNS lymphoma" OR PCNSL | 5 |
| Methods | "central nervous system lymphoma" OR PCNSL OR "CNS lymphoma" | 2 |
| Ratios | temozolomide AND rituximab | 0 |
| Ratios | "high-dose methotrexate" OR "high dose methotrexate" | 3 |
| Ratios | ibrutinib OR zanubrutinib OR acalabrutinib OR pirtobrutinib | 71 |
| Ratios | "diffuse large B-cell lymphoma" AND (relapsed OR refractory) | 41 |
| Weights | "whole brain radiotherapy" OR "whole brain radiation" OR "whole-brain radiotherapy" | 41 |
| Methods | tirabrutinib OR "ONO-4059" OR Velexbru | 0 |
| Ratios | "autologous stem cell transplantation" AND lymphoma | 15 |